Neuromuscular Diseases
Read Time: 5 mins

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Vaccinations: Examining the Current Literature on Vaccinations and the Onset or Worsening of CIDP Symptoms

Copy Link
Published Online: Jul 15th 2021 touchREVIEWS in Neurology. 2021;17(1):3-5 DOI:
Authors: Victoria Chisholm, Nitin Butala, Travis M Smith
Quick Links:
Article Information

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a disease that is remarkably similar to GuillainBarré syndrome (GBS). Like GBS, CIDP is believed to have an association with vaccination. However, the research between CIDP and vaccination is relatively new and intertwined with research on GBS. Public guidelines currently suggest the revaccination of both patient populations. However, the limited amount of available research regarding the relationship between CIDP and vaccination calls into question the safety of current guidelines to revaccinate patients with CIDP. This report reviews the current available literature on CIDP and vaccinations.


CIDP, vaccinations, chronic inflammatory demyelinating polyneuropathy, Guillian–Barré, demyelination, peripheral nerve disorder, chronic relapsing polyneuropathy


Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired progressive sensorimotor neuropathy of the peripheral nerves and nerve roots that appears to be immune-mediated by both the cellular and humoral immune systems. It is caused by chronic damage to the myelin sheaths of the neurons of the peripheral nervous system. It has a variable prognosis, with many patients experiencing a relapsing and remitting course, but does respond well to medical therapy.1 The contributing factors to the development of CIDP are highly debated, and no single mechanism has been defined. However, some reports indicate that a number of cases may have been a result of viral illness or vaccination.2,3 CIDP shares many common events and effects as Guillain–Barré syndrome (GBS), such as areflexia, slowed nerve conduction and increased cerebrospinal fluid (CSF) protein. Thus, the two are often linked in research.4 However, unlike GBS, CIDP has a longer onset of symptoms, with diagnostic criteria placing the onset of symptoms over at least an 8-week period.1 The relationship between GBS and vaccination was first proposed in 1976, when a mild increase in cases was observed up to 8 weeks following vaccination against swine flu.5,6 While the majority of cases of CIDP are not linked to vaccination, the possibility of vaccination as an antecedent event for some cases of CIDP has called into question the safety of giving vaccines to patients currently suffering from CIDP. The GBS/CIDP Foundation International currently recommends that patients diagnosed with either condition within 2 weeks of receiving a vaccine should not receive the same vaccine again.7 All other cases should be discussed with the patient’s neurologist before receiving vaccinations. In this study, we will review data regarding vaccination as an antecedent event to CIDP and data regarding the use of vaccines in patients with a current diagnosis of CIDP.


An extensive search of “CIDP,” “CIDP and vaccines” and “CIDP vaccines” was conducted using PubMed, Google Scholar, Up to Date and Medscape. Articles discussing vaccinations as an antecedent event of CIDP and articles discussing vaccination administration to patients with previously diagnosed CIDP are included in this study. Articles were limited to those published in English between 1 January 1995 to 1 April 2020. Articles under consideration were reviewed and divided into two categories: articles that addressed vaccination as an antecedent event to CIDP and articles that addressed the administration of vaccines to patients with existing CIDP. Articles were further divided by article type: case study, case series, database review and research study.


Four articles were found discussing vaccination as an antecedent event to CIDP: two case studies, one case series, and one database review (Table 1). Of the two case studies, one reported a case following the influenza vaccine and the other following the AH1N1 influenza vaccination.2,8 The case series identified three cases following the influenza vaccine.9 The case following the AH1N1 vaccine, presented by Remiche et al., was unique in that the patient was found to have an underlying hereditary neuropathy.2 The fourth article was a review of the Italian CIDP database that reviewed data on the anteceding events of 411 patients, where 1.5% claimed vaccinations 1–42 days before the onset of CIDP.10

Three articles were discovered discussing the worsening of CIDP symptoms following subsequent vaccinations.1113 All articles discussing the recurrence of CIDP following routine vaccines combined data from patients with GBS and those with CIDP (Table 1). The studies of Kuitwaard et al. and Pritchard et al. reported fewer patients with CIDP compared with patients with GBS, with one study including 76 patients with CIDP out of a total of 321 who completed the questionnaire, and the other only including 179 patients with CIDP out of a total of 1,114.11,12 Furthermore, both studies included a small sample size of patients who received a vaccine following their initial diagnosis, with 24 out of the 76 in the Kuitwaard et al. study and 65 of the 179 in the Pritchard et al. study. Both studies reported a higher proportion of patients with CIDP experiencing worsening of their symptoms following the administration of a vaccine relative to that of patients with GBS; 11% of the patients with CIDP reported worsening symptoms compared with only 2.6% of patients with GBS.11,12 However, the percentage of patients with worsening symptoms was different between the two studies. In the study by Kuitwaard et al., 5 out of 24 (20%) patients with CIDP experienced worsening symptoms after receiving a flu vaccine, compared to 5 out of 65 (8%) in the study performed by Pritchard et al.11,12 This is most likely a product of the small sample sizes of each study.

The third study, by Hughes et al., did not differentiate between patients with CIDP and GBS, reporting a total of 110 patients that had either CIDP or GBS.13 They reported two possible cases of relapse following subsequent vaccinations, one recurrence of GBS following several different immunizations and one report of relapse of peripheral neuropathy following tetanus immunizations. The total number of patients who received vaccinations following their initial diagnosis was not reported in the study.


One of the difficulties of establishing antecedent events to CIDP is the chronic nature of the disease. The onset of CIDP, by clinical criteria, must take place over 8 weeks.1 This makes attributing a single event to the beginning of the disease difficult, as the actual date of disease onset is rarely straightforward. Overall, there is very little literature reviewing the association between vaccination and the onset of CIDP. Out of four available reports on the possible association, two were case studies, and one was a case series. The full database analysis showed that out of 411 patients who reported an event prior to diagnosis, only 1.5% had received vaccinations.10 Furthermore, the case report presented by Remiche et al. described a pre-existing neurological disease that may have influenced the development of CIDP following vaccination.2 Thus, of the available data, there are only 13 cases identifying vaccination as an antecedent event to CIDP, with one case that may be confounded by a pre-existing underlying illness.

The reports addressing the use of vaccines in patients with a prior CIDP diagnosis are also limited in number, and those available contradict each other at times. The percentage of patients with CIDP that develop worsening symptoms was far greater in the study by Kuitwaard et al. than in the study by Pritchard et al., with 20% versus 8% of CIDP patients experiencing worsening symptoms reported by Kuitwaard and Pritchard, respectively.11,12 Furthermore, the study by Hughes et al. reported only one patient with continuously relapsing peripheral neuropathy following vaccinations.13 This may be due, in part, to the overall small size of all three reviews and the larger sample size included in the study by Pritchard et al.12 Furthermore, only 89 patients with CIDP were represented between the studies by Pritchard et al. and Kuitwaard et al., contrasting with the much larger sample size of 417 patients with GBS. In both studies, the rate of worsening symptoms in CIDP was higher than the rate of GBS recurrence of 0% and 4%, respectively.11,12 This may be related to the larger sample size of patients with GBS present in both studies, as well as the relapsing, remitting nature of CIDP itself. Hughes et al. did not report the number of patients with CIDP versus those GBS included in their study.13


Given the limited amount of information regarding CIDP and vaccines, more research is required to determine further if there is genuinely a correlation between vaccination and CIDP. While the available data show a possible association, it is also limited in quantitative data and a definitive association cannot be determined. Furthermore, the chronic onset of CIDP makes determining antecedent and contributing events difficult. Also, the relapsing and remitting nature of the disease makes it difficult to assess whether worsening symptoms following revaccination can be attributed to the vaccine itself. Therefore, we feel that more information is needed in order to determine if vaccinations are safe to use in patients with CIDP, as the studies in our review showed cases of both the development of CIDP after vaccination and the worsening of CIDP symptoms following revaccination. Future studies should be conducted with larger sample sizes of CIDP patients to establish proper guidelines for this disease.

Article Information:

Victoria Chisholm, Nitin Butala and Travis M Smith have nothing to disclose in relation to this article.

Compliance With Ethics

This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Review Process

Double-blind peer review.


The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.


Victoria Chisholm, 27463 County Road 127, Sanderson, FL 32087, USA. E:


No funding was received in the publication of this article.


This article is freely accessible at © Touch Medical Media 2021.




  1. Peltier AC, Donofrio PD. Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside. Semin Neurol. 2012;32:187–95.
  2. Remiche G, Abramowicz M, Mavroudakis N. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) associated to hereditary neuropathy with liability to pressure palsies (HNPP) and revealed after influenza AH1N1 vaccination. Acta Neurologica Belgica. 2013;113:519–22.
  3. Broers MC, Bunschoten C, Nieboer D, et al. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: A systematic review and meta-analysis. Neuroepidemiology. 2019;52:161–72.
  4. Ramachandran TS, Sater RA. How do the clinical features of Guillain-Barré syndrome (GBS) compare with chronic inflammatory demyelinating polyneuropathy (CIDP)? 2018. Available at: 15 June 2021).
  5. Centers for Disease Control and Prevention. Guillain-Barré Syndrome and Vaccines. 2019. Avalable at: 15 June 2020).
  6. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol.1979;110:105–23.
  7. GBS|CIDP Foundation International. Should I get the flu vaccine if I have had GBS or have CIDP? Available at: 17 March 2021).
  8. Brostoff J, Beitverda Y, Birns J. Post-influenza vaccine chronic inflammatory demyelinating polyneruopathy. Age Ageing. 2008;37:229–30.
  9. Kelkar P. Chronic inflammatory demyelinating polyneuropathy (CIDP) with rapid progression after influenza vaccination: a report of three cases. J Clin Neuromusc Dis. 2006;8:20–5.
  10. Doneddu P, Bianchi E, Cocito D, et al. Risk factors for CIDP: Antecedent events, lifestyle and dietary habits. Data from the Italian CIDP database. Eur J Neurol. 2019;27:136–43.
  11. Kuitwaard K, Bos‐Eyssen M, Blomkwist‐Markens P, Van Doorn P. Recurrences, vaccinations and long‐term symptoms in GBS and CIDP. J Peripher Nerv Sys. 2009;14:310–5.
  12. Pritchard J, Mukherjee R, Hughes RAC. Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunization. J Neurol Neurosurg Psychiatr.2002;73,348–49.
  13. Hughes RA, Choudhary PP, Osborn M, et al. Immunization and risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 1996;19:1230–1.

Further Resources

Share this Article
Related Content In Neuromuscular Diseases
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72